Abstract
As a ubiquitous nuclear protein, high-mobility group box 1 (HMGB1) is constitutively expressed and can be actively secreted by macrophages/monocytes, as well as passively released from damaged cells following pathological injuries. Studies indicate that HMGB1 functions as a mediator of infection- and injury-elicited inflammatory diseases. Although intracellular HMGB1 functions as a regulator of tumorigenesis, epigenetic anticancer agents or therapeutic γ-ray irradiation could also cause active secretion or passive release of HMGB1, enabling serum HMGB1 to serve as a biomarker for the diagnosis and therapy of various cancers. Here we describe a semiquantitative immune blotting method to measure HMGB1 in human serum, in comparison with a commercially available HMGB1 enzyme-linked immunosorbent assay (ELISA) technique.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
References
Wang H, Bloom O, Zhang M et al (1999) HMG-1 as a late mediator of endotoxin lethality in mice. Science 285:248–251
Bonaldi T, Talamo F, Scaffidi P et al (2003) Monocytic cells hyperacetylate chromatin protein HMGB1 to redirect it towards secretion. EMBO J 22:5551–5560
Lotze MT, Tracey KJ (2005) High-mobility group box 1 protein (HMGB1): nuclear weapon in the immune arsenal. Nat Rev Immunol 5:331–342
Ivanov S, Dragoi AM, Wang X et al (2007) A novel role for HMGB1 in TLR9-mediated inflammatory responses to CpG-DNA. Blood 110:1970–1981
Rendon-Mitchell B, Ochani M, Li J et al (2003) IFN-gamma induces high mobility group box 1 protein release partly through a TNF-dependent mechanism. J Immunol 170:3890–3897
Tang D, Shi Y, Kang R et al (2007) Hydrogen peroxide stimulates macrophages and monocytes to actively release HMGB1. J Leukoc Biol 81:741–747
Scaffidi P, Misteli T, Bianchi ME (2002) Release of chromatin protein HMGB1 by necrotic cells triggers inflammation. Nature 418:191–195
Wang H, Ward MF, Fan XG et al (2006) Potential role of high mobility group box 1 in viral infectious diseases. Viral Immunol 19:3–9
Zhu S, Li W, Ward MF et al (2010) High mobility group box 1 protein as a potential drug target for infection- and injury-elicited inflammation. Inflamm Allergy Drug Targets 9:60–72
Wang H, Ward MF, Sama AE (2009) Novel HMGB1-inhibiting therapeutic agents for experimental sepsis. Shock 32:348–357
Wang H, Yang H, Tracey KJ (2004) Extracellular role of HMGB1 in inflammation and sepsis. J Intern Med 255:320–331
Wang H, Li W, Goldstein R, Tracey KJ, Sama AE (2007) HMGB1 as a potential therapeutic target. Novartis Found Symp 280:73–85
Wang H, Zhu S, Zhou R et al (2008) Therapeutic potential of HMGB1-targeting agents in sepsis. Expert Rev Mol Med 10:e32
Kang R, Xie Y, Zhang Q et al (2017) Intracellular HMGB1 as a novel tumor suppressor of pancreatic cancer. Cell Res 27:916–932
Jiao Y, Wang HC, Fan SJ (2007) Growth suppression and radiosensitivity increase by HMGB1 in breast cancer. Acta Pharmacol Sin 28:1957–1967
Liu P, Zhao L, Loos F et al (2018) Epigenetic anticancer agents cause HMGB1 release in vivo. Oncoimmunology 7:e1431090
Wang L, He L, Bao G et al (2016) Ionizing radiation induces HMGB1 cytoplasmic translocation and extracellular release. Guo Ji Fang She Yi Xue He Yi Xue Za Zhi 40:91–99
Bald T, Quast T, Landsberg J et al (2014) Ultraviolet-radiation-induced inflammation promotes angiotropism and metastasis in melanoma. Nature 507:109–113
Kargi A, Demirpence O, Gunduz S et al (2016) Serum levels of HMGB1 have a diagnostic role in metastatic renal cell cancer. Cancer Biomark 17:17–20
Napolitano A, Antoine DJ, Pellegrini L et al (2016) HMGB1 and its hyperacetylated isoform are sensitive and specific serum biomarkers to detect asbestos exposure and to identify mesothelioma patients. Clin Cancer Res 22:3087–3096
Urbonaviciute V, Furnrohr BG, Weber C et al (2007) Factors masking HMGB1 in human serum and plasma. J Leukoc Biol 81:67–74
Sha Y, Zmijewski J, Xu Z, Abraham E (2008) HMGB1 develops enhanced proinflammatory activity by binding to cytokines. J Immunol 180:2531–2537
Lehner J, Wittwer C, Fersching D et al (2012) Methodological and preanalytical evaluation of an HMGB1 immunoassay. Anticancer Res 32:2059–2062
He RL, Zhou J, Hanson CZ et al (2009) Serum amyloid A induces G-CSF expression and neutrophilia via Toll-like receptor 2. Blood 113:429–437
Yasuda T, Ueda T, Takeyama Y et al (2006) Significant increase of serum high-mobility group box chromosomal protein 1 levels in patients with severe acute pancreatitis. Pancreas 33:359–363
Gaini S, Pedersen SS, Koldkjaer OG et al (2007) High mobility group box-1 protein in patients with suspected community-acquired infections and sepsis: a prospective study. Crit Care 11:R32
Okazaki K, Kondo M, Kato M et al (2008) Elevation of high-mobility group box 1 concentration in asphyxiated neonates. Neonatology 94:105–109
Karlsson S, Pettila V, Tenhunen J et al (2008) HMGB1 as a predictor of organ dysfunction and outcome in patients with severe sepsis. Intensive Care Med 34(6):1046–1053
Rowe SM, Jackson PL, Liu G et al (2008) Potential role of high-mobility group box 1 in cystic fibrosis airway disease. Am J Respir Crit Care Med 178:822–831
Yoshizaki A, Komura K, Iwata Y et al (2009) Clinical significance of serum HMGB-1 and sRAGE levels in systemic sclerosis: association with disease severity. J Clin Immunol 29:180–189
Chung HW, Lee SG, Kim H et al (2009) Serum high mobility group box-1 (HMGB1) is closely associated with the clinical and pathologic features of gastric cancer. J Transl Med 7:38. https://doi.org/10.1186/1479-5876-7-38
Dupire G, Nicaise C, Gangji V, Soyfoo MS (2012) Increased serum levels of high-mobility group box 1 (HMGB1) in primary Sjogren’s syndrome. Scand J Rheumatol 41:120–123
Lee H, Song M, Shin N et al (2012) Diagnostic significance of serum HMGB1 in colorectal carcinomas. PLoS One 7:e34318
Wang H, Yang H, Czura CJ, Sama AE, Tracey KJ (2001) HMGB1 as a late mediator of lethal systemic inflammation. Am J Respir Crit Care Med 164:1768–1773
Angus DC, Yang L, Kong L et al (2007) Circulating high-mobility group box 1 (HMGB1) concentrations are elevated in both uncomplicated pneumonia and pneumonia with severe sepsis. Crit Care Med 35:1061–1067
Kazama H, Ricci JE, Herndon JM et al (2008) Induction of immunological tolerance by apoptotic cells requires caspase-dependent oxidation of high-mobility group box-1 protein. Immunity 29:21–32
Park JS, Arcaroli J, Yum HK et al (2003) Activation of gene expression in human neutrophils by high mobility group box 1 protein. Am J Physiol Cell Physiol 284:C870–C879
Li W, Li J, Sama AE, Wang H (2013) Carbenoxolone blocks endotoxin-induced PKR activation and HMGB1 release. Mol Med 19:203–211
Li W, Li J, Ashok M et al (2007) A cardiovascular drug rescues mice from lethal sepsis by selectively attenuating a late-acting proinflammatory mediator, high mobility group box 1. J Immunol 178:3856–3864
Wang H, Liao H, Ochani M et al (2004) Cholinergic agonists inhibit HMGB1 release and improve survival in experimental sepsis. Nat Med 10:1216–1221
Li W, Zhu S, Li J et al (2011) A hepatic protein, fetuin-A, occupies a protective role in lethal systemic inflammation. PLoS One 6:e16945
Li W, Ashok M, Li J et al (2007) A major ingredient of green tea rescues mice from lethal sepsis partly by inhibiting HMGB1. PLoS One 2:e1153
Yang H, Ochani M, Li J et al (2004) Reversing established sepsis with antagonists of endogenous high-mobility group box 1. Proc Natl Acad Sci U S A 101:296–301
Manganelli V, Signore M, Pacini I et al (2010) Increased HMGB1 expression and release by mononuclear cells following surgical/anesthesia trauma. Crit Care 14:R197
Zhou Y, Xiong KL, Lin S et al (2010) Elevation of high-mobility group protein box-1 in serum correlates with severity of acute intracerebral hemorrhage. Mediat Inflamm 2010:142458. https://doi.org/10.1155/2010/142458. Epub 2010 Sep 29
Bruchfeld A, Wendt M, Bratt J et al (2011) High-mobility group box-1 protein (HMGB1) is increased in antineutrophilic cytoplasmatic antibody (ANCA)-associated vasculitis with renal manifestations. Mol Med 17:29–35
Shang GH, Jia CQ, Tian H et al (2009) Serum high mobility group box protein 1 as a clinical marker for non-small cell lung cancer. Respir Med 103:1949–1953
Goldstein RS, Gallowitsch-Puerta M, Yang L et al (2006) Elevated high-mobility group box 1 levels in patients with cerebral and myocardial ischemia. Shock 25:571–574
Acknowledgments
Work in the authors’ laboratory was supported by grants from the National Institutes of Health (R01GM063075 and R01AT005076).
Author information
Authors and Affiliations
Corresponding author
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 2020 Springer Science+Business Media, LLC, part of Springer Nature
About this protocol
Cite this protocol
Chen, W., Bao, G., Zhao, L., Wang, H. (2020). Analysis of Circulating HMGB1 in Human Serum. In: Vancurova, I., Zhu, Y. (eds) Immune Mediators in Cancer. Methods in Molecular Biology, vol 2108. Humana, New York, NY. https://doi.org/10.1007/978-1-0716-0247-8_2
Download citation
DOI: https://doi.org/10.1007/978-1-0716-0247-8_2
Published:
Publisher Name: Humana, New York, NY
Print ISBN: 978-1-0716-0246-1
Online ISBN: 978-1-0716-0247-8
eBook Packages: Springer Protocols